References
- Alkharfy KM, Ahmad A, Jan BL, Raish M. (2018). Thymoquinone reduces mortality and suppresses early acute inflammatory markers of sepsis in a mouse model. Biomed Pharmacother 98:801–5.
- Alkharfy KM, Ahmad A, Khan RM, Al-Shagha WM. (2015a). Pharmacokinetic plasma behaviors of intravenous and oral bioavailability of thymoquinone in a rabbit model. Eur J Drug Metab Pharmacokinet 40:319–23.
- Alkharfy KM, Ahmad A, Raish M, Vanhoutte PM. (2015b). Thymoquinone modulates nitric oxide production and improves organ dysfunction of sepsis. Life Sci 143:131–8.
- Alkharfy KM, Al-Daghri NM, Al-Attas OS, Alokail MS. (2011). The protective effect of thymoquinone against sepsis syndrome morbidity and mortality in mice. Int Immunopharmacol 11:250–4.
- Al-Majed AA, Al-Omar FA, Nagi MN. (2006). Neuroprotective effects of thymoquinone against transient forebrain ischemia in the rat hippocampus. Eur J Pharmacol 543:40–7.
- Badary OA, Abd-Ellah MF, El-Mahdy MA, et al. (2007). Anticlastogenic activity of thymoquinone against benzo(a)pyrene in mice. Food Chem Toxicol 45:88–92.
- Bosilkovska M, Walder B, Besson M, et al. (2012). Analgesics in patients with hepatic impairment. Drugs 72:1645–69.
- Brockmoller J, Thomsen T, Wittstock M, et al. (2005). Pharmacokinetics of levetiracetam in patients with moderate to severe liver cirrhosis (Child-Pugh classes A, B, and C): characterization by dynamic liver function tests. Clin Pharmacol Ther 77:529–41.
- Caldwell GW, Wu WN, Masucci JA, et al. (2005). Metabolism and excretion of the antiepileptic/antimigraine drug, topiramate in animals and humans. Eur J Drug Metab Pharm 30:151–64.
- El Gazzar M, El Mezayen R, Marecki JC, et al. (2006). Anti-inflammatory effect of thymoquinone in a mouse model of allergic lung inflammation. Int Immunopharmacol 6:1135–42.
- Flaharty KK, Caro J, Erslev A, et al. (1990). Pharmacokinetics and erythropoietic response to human recombinant erythropoietin in healthy men. Clin Pharmacol Ther 47:557–64.
- Gali-Muhtasib H, Roessner A, Schneider-Stock R. (2006). Thymoquinone: a promising anti-cancer drug from natural sources. Int J Biochem Cell Biol 38:1249–53.
- Glue P, Sulowicz W, Colucci R, et al. (2003). Single-dose pharmacokinetics of felbamate in patients with renal dysfunction. Br J Clin Pharmacol 44:91–3.
- Mansour MA. (2000). Protective effects of thymoquinone and desferrioxamine against hepatotoxicity of carbon tetrachloride in mice. Life Sci 66:2583–91.
- Ohnhaus EE. 1978. Bioavailability of digoxin in renal insufficiency and heart failure. Cardiac glycosides. Berlin: Springer, 181–6.
- Patsalos PN. (2005). Properties of Antiepileptic Drugs in the Treatment of Idiopathic Generalized Epilepsies. Epilepsia 46:140–8.
- Rodighiero V. (1999). Effects of liver disease on pharmacokinetics. Clin Pharm 37:399–431.
- Sayed MD. (1980). Traditional medicine in health care. J Ethnopharmacol 2:19–22.
- St. Peter WL. (2010). Improving medication safety in chronic kidney disease patients on dialysis through medication reconciliation. Adv Chronic Kidney Dis 17:413–9.
- Talbi A, Zhao D, Liu QW, et al. (2014). Pharmacokinetics, tissue distribution, excretion and plasma protein binding studies of wogonin in rats. Molecules 19:5538–49.
- Wollam J, Antebi A. (2011). Sterol regulation of metabolism, homeostasis, and development. Annu Rev Biochem 80:885–916.
- Woo CC, Kumar AP, Sethi G, Tan K. (2012). Thymoquinone: potential cure for inflammatory disorders and cancer. Biochem Pharmacol 83:443–51.
- Wynne H. (2005). Drug metabolism and ageing. Br Menopause Soc J 11:51–6.